Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Notes Payables (2020 - 2025)

SAB Biotherapeutics (SABS) has disclosed Notes Payables for 6 consecutive years, with $138554.0 as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Notes Payables fell 83.42% year-over-year to $138554.0, compared with a TTM value of $138554.0 through Mar 2025, down 83.42%, and an annual FY2024 reading of $275849.0, down 73.75% over the prior year.
  • Notes Payables was $138554.0 for Q1 2025 at SAB Biotherapeutics, down from $275849.0 in the prior quarter.
  • Across five years, Notes Payables topped out at $1.8 million in Q4 2021 and bottomed at $25013.0 in Q3 2022.
  • Average Notes Payables over 5 years is $609781.8, with a median of $541644.0 recorded in 2023.
  • The sharpest move saw Notes Payables soared 2065.45% in 2023, then crashed 83.42% in 2025.
  • Year by year, Notes Payables stood at $1.8 million in 2021, then crashed by 57.0% to $772665.0 in 2022, then soared by 36.0% to $1.1 million in 2023, then plummeted by 73.75% to $275849.0 in 2024, then crashed by 49.77% to $138554.0 in 2025.
  • Business Quant data shows Notes Payables for SABS at $138554.0 in Q1 2025, $275849.0 in Q4 2024, and $615818.0 in Q2 2024.